Chimeric Therapeutics (ASX: CHM) extends closing date for AU$10Mn entitlement offer to 30 November - Kalkine Media

November 15, 2023 11:19 AM AEDT | By Team Kalkine Media

Chimeric Therapeutics (ASX: CHM) extends closing date for AU$10Mn entitlement offer to 30 November — Image source: Company PPT

Recent News

/C O R R E C T I O N -- Addverb/

Energy Performance and Multifamily Housing Asset Value

135th Canton Fair Showcases High-End Stationery, Ushering in New Busin...

CleverTap launches Clever.AI, the AI-Driven Edge for Customer Engageme...

Highlights

CHM has extended the closing date for entitlement offer designed to raise ~AU$10 million.

The offer will now close on 30 November.

CHM, a cell therapy company, is currently engaged in advancing four ongoing clinical trials.

Chimeric Therapeutics Limited (ASX: CHM) has extended the closing date of the non-renounceable entitlement offer announced in October 2023.

The entitlement offer, which is designed to raise ~AU$10 million, is now due to close on 5 pm (Sydney time) on 30 November 2023.

The entitlement offer is for 2 new fully paid ordinary shares in the company for every 3 fully paid ordinary shares held by eligible shareholders as at the end of October.

The shares are planned to be issued at a price of AU$0.028 per new share. Trading of new shares is expected to commence on 8 December 2023.

Data source: company update

To know more, read here.

CHM shares traded at AU$0.029 at the time of writing on 15 November 2023.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024

Markets

Disclaimer